Gosogliptin
 | |
| Clinical data | |
|---|---|
| Other names | PF-734200 |
| Identifiers | |
| |
JSmol) | |
| |
| |
Gosogliptin (
type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors (also called gliptins). It was discovered[1] and developed through Phase 1[2][3][4] and Phase 2[5][6][7] by Pfizer. The crystal structure of DPP-4 in complex with gosogliptin is available.[8] Its metabolism, excretion and pharmacokinetics in rat, dog and human have been described.[9] A cost efficient route has been published.[10] Other studies[11] including Phase 3 studies were conducted in Russia.[12][13] It is approved for use in Russia.[14]
References
- PMID 19275964.
- S2CID 13417601.
- PMID 21366665.
- PMID 22541754.
- S2CID 205550845.
- ^ "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of 12-Week Administration of PF-00734200 to Subjects with Type 2 Diabetes Mellitus and Insufficient Glycemic Control on Metformin Treatment". 9 June 2011.
- ^ "A Phase 2a, Randomized, Placebo-Controlled, Parallel Group, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of 12-Week Oral Administration of PF-00734200 Tablets to Subjects with Type 2 Diabetes Mellitus on Stable Treatment with Metformin". 22 June 2010.
- ^ "RCSB PDB - 3F8S: Crystal structure of dipeptidyl peptidase IV in complex with inhibitor".
- S2CID 14277073.
- .
- .
- doi:10.14341/DM7233.
- ^ "Evaluate Efficacy and Safety of Gosogliptin as Monotherapy and in Combination with Metformin vs. Vildagliptin as Monotherapy and in Combination with Metformin in Drug-naive Type 2 Diabetic Patients". 18 March 2017.
- ^ "SatRx LLC Announces First Registration in Russia of SatRx (gosogliptin), an Innovative Drug for Treatment of Type 2 Diabetes" (Press release). SatRx LLC.